CMS-121 是喹诺酮衍生物，对乙酰辅酶 A 羧化酶 1 具有抑制作用，具有口服活性。CMS-121具有保护 HT22 细胞免受缺血和氧化损伤的活性，EC50分别为7 nM和200 nM。CMS-121具有强大的抗炎，抗氧化，神经保护和肾保护作用。

CMS-121, a quinolone derivative, is an orally active acetyl-CoA carboxylase 1 (ACC1) inhibitor. CMS-121 protects HT22 cells against ischemia and oxidative damage (EC50: 7 nM and 200 nM). CMS-121 shows strong neuroprotective, antioxidative, anti-inflammatory, and renoprotective activities.

CMS-121 can increase acetyl-CoA in cells. CMS-121 (1 μM; 4 hours; HT22 cells) treatment also increases the phosphorylation of ACC1 at serine 79.[1].

CMS-121 preserves mitochondrial homeostasis by regulating acetyl-coenzyme A (acetyl-CoA) metabolism. CMS-121 (~20 mg/kg; p.o; daily; for 4 months; female SAMP8 mice) treatment decreases cognitive decline and metabolic and transcriptional markers of aging in the brain when administered to rapidly aging SAMP8 mice. [1].

1353224-53-9

C20H19NO3

321.37

CMS121

DMSO:50mg/mL (155.58mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years